Lisata Therapeutics, Inc.

Stage 4 · Declining · week 13

As of Oct 22, 2026, Lisata Therapeutics is in Stage 4, the downtrend phase, now in week 13 (since Jul 24, 2026). It closed at $1.01, 80.0% below its 52-week high and below its 200-day average, which is falling.

$1.01

-3.81% today

$10.9M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is LSTA early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 14w

S1 13w

S4 14w

S4 21w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S3 1w → S4 14w → S1 13w → S2 10w → S3 5w → S2 10w → S3 6w → S4 14w → S1 5w → S4 14w → S1 13w → S3 1w → S4 21w → S1 1w → S2 12w → S3 12w → S4 13w current

Total tracked: 166 weeks across 17 stage runs.

LSTA among Biotechnology386th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…386	LSTALisata Therapeutics, Inc.	Stage 4 · wk 13	19	−29.9%

vs 52W High

-80.0%

$0.99 lo$5.04 hi

80.0% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 13

1w13w26w

Week 13, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-66.6%

200 DMA: $3.02 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.08x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-29.9%

-39.5%

-69.7%

YTD

-48.5%

-57.9%

Scan Membership

Breakout Watch

Latest: 2024-06-17

6 appearances in last 60 days. First seen: 2018-10-16.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 13 · Vol 0.08x

2026-10-21S4

Wk 13 · Vol 0.14x

2026-10-20S4

Wk 13 · Vol 0.33x

2026-10-19S4

Wk 13 · Vol 0.28x

2026-10-16S4

Wk 12 · Vol 0.16x

2026-10-15S4

Wk 12 · Vol 0.07x

2026-10-14S4

Wk 12 · Vol 0.23x

2026-10-13S4

Wk 12 · Vol 0.42x

2026-10-12S4

Wk 12 · Vol 0.48x

2026-10-09S4

Wk 11 · Vol 0.81x

2026-10-08S4

Wk 11 · Vol 2.08x

2026-10-07S4

Wk 11 · Vol 0.04x

Moving averages & range

50 DMA

$1.40

200 DMA

$3.02

52W High

$5.04

52W Low

$0.99

5D Low

$1.00

Resistance levels (recent highs)

20d High

$1.58

60d High

$1.90

120d High

$3.75

250d High

$5.04

Next resistance

+56.4%

to 20d High

ROE

-101.7%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 1.1

Lisata Therapeutics: quick answers

What stage is Lisata Therapeutics in?

As of Oct 22, 2026, Lisata Therapeutics (LSTA) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 24, 2026 and is in week 13. What the four stages mean

Is Lisata Therapeutics in an uptrend?

No. Lisata Therapeutics is in a Stage 4 downtrend. It trades 66.6% below its 200-day average, which is falling.

How far is Lisata Therapeutics from its 52-week high?

Lisata Therapeutics closed at $1.01 on Oct 22, 2026, 80.0% below its 52-week high of $5.04. Its 52-week low is $0.99.

How has Lisata Therapeutics performed over the past year?

As of Oct 22, 2026, Lisata Therapeutics is down 57.9% over the past year and down 48.5% so far in 2026.

Which sector and industry is Lisata Therapeutics in?

Lisata Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. Lisata Therapeutics, Inc. was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. in September 2022. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.